Use of Neurotrophic Factor-alpha1/Carboxypeptidase E (CPE) to Treat Alzheimer Disease
Summary:
The NICHD is seeking licensees for development of Carboxypeptidase E (CPE) as a therapy for MCI or AD.
Codon-optimization of HIV-1 Viral Infectivity Factor (VIF) Gene
Expression of the HIV-1 Vif protein in the absence of other viral factors such a Tat and Rev is extremely inefficient due to the presence of inhibitory sequences on its mRNA. This invention uses codon optimization to remove such inhibitory sequences without altering the amino acid sequence of the protein. The modified vif gene in the resulting pcDNA -hVIF vector is expressed under the control of the CMV promoter. In this, the protein functions as wild type and is more amendable to high-level expression in mammalian cells.
Lentiviral Vectors with Dual Fluorescence/Luminescence Reporters
In research settings, visualization of tumors or tumor cells is often done using either bioluminescence or fluorescence. However, both of these methods have shortcomings: bioluminescence is not sensitive enough to sort individual tumor cells, and fluorescence cannot be used effectively to view internal tumors and is best used with surface tumors.
Replication-Competent VSV–BDBV Vaccine for Rapid Prevention and Post- Exposure Protection Against Bundibugyo Virus
Bundibugyo virus (BDBV) is one of several ebolaviruses that cause Ebola virus disease (EVD). Sporadic outbreaks continue to occur in Central Africa, highlighting the need for effective vaccines that provide rapid protection.
RP2 and RPGR Vectors For Treating X-linked Retinitis Pigmentosa
X-linked forms of retinitis pigmentosa (XLRP) are relatively severe blinding disorders, resulting from progressive photoreceptor dysfunction primarily caused by mutations in RPGR or RP2 gene.
Novel Chemoattractant-Based Toxins To Improve Vaccine Immune Responses for Cancer and Infectious Diseases
Description of Technology:
Cancer is one of the leading causes of death in United States and it is estimated that there will be more than half a million deaths caused by cancer in 2009. A major drawback of the current chemotherapy-based therapeutics is the cytotoxic side-effects associated with them. Thus there is a dire need to develop new therapeutic strategies with fewer side-effects. Immunotherapy has taken a lead among the new therapeutic approaches. Enhancing the innate immune response of an individual has been a key approach for the treatment against
Novel Dopamine Receptor Ligands As Therapeutics For Central Nervous System Disorders
Summary:
The National Institute on Drug Abuse's Medications Discovery Research Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize 4-phenylpiperazine derivatives as dopamine D3 selective ligands.
Human Antibodies Targeting Beneficial Viral Peptide in Liver Cancer
Summary:
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees to develop a collection of anti-CE1 antibodies for liver cancer treatment.
MC38 B2m KO Cell Line
Summary:
The National Cancer Institute (NCI) seeks licensees for a CRISPR/Cas9-engineered MC38 B2m knockout murine colon cancer cell line that models tumor resistance to PD-1/PD-L1 checkpoint blockade caused by loss of MHC-I antigen presentation. This research tool provides an opportunity to study checkpoint-refractory tumors and evaluate alternative or combination immunotherapy strategies for cancers that evade conventional T-cell–mediated recognition.
Quantitative Particle Identification (QPID) Digital Autoradiography System
Summary:
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a Quantitative Particle Identification (QPID) digital autoradiography system with particle identification capabilities.